06. 01. 2026
Oxaliplatin resistance in colorectal cancer
Thursday 4. 6. 2026 | 14:00 hod.
Turquoise Lecture Hall of the IEM CAS (building Lb, 2nd floor)
Lecturer: Saba Selvi, MSc | Department of the Molecular Biology of Cancer
Annotation: Colorectal cancer (CRC) is the third most common and lethal cancer worldwide. Most of the patients are diagnosed at the advanced (metastatic) stages due to a lack of specific symptoms. Oxaliplatin is a widely used chemotherapeutic for the treatment of metastatic CRC. Although oxaliplatin-based therapies have been shown to reduce the risk of disease recurrence and death, the success of these therapies is limited due to acquired resistance, which remains the major obstacle for advanced-stage CRC patients. In our study, we investigated potential mitochondrial biomarkers associated with oxaliplatin resistance, considering differences in genetic backgrounds and tumour heterogeneity.